NASDAQ:SGYP - Synergy Pharmaceuticals Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
News Sentiment
About
FAQ

Consensus Rating: N/A
Consensus Price Target: $0.00
Forecasted Upside: NaN
Number of Analysts: 0
Breakdown:
0 Sell Ratings
0 Hold Ratings
0 Buy Ratings
0 Strong Buy Ratings

^$0.00 As of 07/10/2020 01:00 AM ET

+0.30 (1.20%)

Get New Synergy Pharmaceuticals Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for SGYP and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SGYP

^$0.00

This price target is based on 0 analysts offering 12 month price targets for Synergy Pharmaceuticals in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a NaN upside from the last price of $0.00.

Current Consensus is N/A

The current consensus among 0 investment analysts is to n/a stock in Synergy Pharmaceuticals. This rating has held steady since September 2019, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
0 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

3/27/2020

0 strong buy ratings
0 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

6/25/2020

0 strong buy ratings
0 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

9/23/2020

0 strong buy ratings
0 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

12/22/2020

0 strong buy ratings
0 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

3/22/2021

0 strong buy ratings
0 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

6/20/2021

0 strong buy ratings
0 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

8/19/2021

0 strong buy ratings
0 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

9/18/2021

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
10/26/2018	Canaccord Genuity	Downgrade	Buy ➝ Hold		N/A
10/26/2018	BTIG Research	Downgrade	Buy ➝ Neutral		N/A
8/7/2018	HC Wainwright	Reiterated Rating	Buy	$7.00	High
6/24/2018	Cantor Fitzgerald	Reiterated Rating	Hold		High
6/6/2018	HC Wainwright	Set Price Target	Buy	$7.00	High
5/14/2018	BTIG Research	Set Price Target	Buy	$7.00	Low
5/13/2018	HC Wainwright	Set Price Target	Buy	$7.00	Low
5/13/2018	Oppenheimer	Reiterated Rating	Hold		Low
5/7/2018	HC Wainwright	Set Price Target	Buy	$7.00	High
3/22/2018	Oppenheimer	Reiterated Rating	Hold		Low
3/5/2018	HC Wainwright	Set Price Target	Buy	$7.00	Medium
3/1/2018	Oppenheimer	Reiterated Rating	Hold		High
2/1/2018	HC Wainwright	Reiterated Rating	Buy	$7.00	High
2/1/2018	Cantor Fitzgerald	Reiterated Rating	Buy		High
1/25/2018	Cantor Fitzgerald	Reiterated Rating	Buy	$10.00	High
1/22/2018	Oppenheimer	Reiterated Rating	Hold		High
1/8/2018	HC Wainwright	Set Price Target	Buy	$7.00	Medium
1/5/2018	Oppenheimer	Reiterated Rating	Outperform ➝ Market Perform	$10.00	High
1/5/2018	CIBC	Reiterated Rating	Outperform ➝ Market Perform		High
1/5/2018	Citigroup	Downgrade	Market Perform		High
1/4/2018	Oppenheimer	Downgrade	Outperform ➝ Market Perform		High
12/4/2017	HC Wainwright	Set Price Target	Buy	$7.00	High
11/21/2017	Cantor Fitzgerald	Reiterated Rating	Buy	$10.00	N/A
11/14/2017	BTIG Research	Reiterated Rating	Buy	$7.00	N/A
11/12/2017	Canaccord Genuity	Set Price Target	Buy	$13.00	N/A
10/18/2017	HC Wainwright	Set Price Target	Buy	$8.00	N/A
10/11/2017	HC Wainwright	Set Price Target	Buy	$8.00	N/A
10/10/2017	Oppenheimer	Set Price Target	Buy	$6.00	N/A
9/25/2017	HC Wainwright	Reiterated Rating	Buy ➝ Buy	$15.00 ➝ $8.00	Low
9/13/2017	Citigroup	Reiterated Rating	Sell ➝ Sell	$3.20 ➝ $2.50	Medium
9/8/2017	BTIG Research	Reiterated Rating	Buy	$11.00	Medium
9/8/2017	CIBC	Lower Price Target	Outperform ➝ Outperform	$9.00 ➝ $6.00	Low
9/8/2017	Cantor Fitzgerald	Reiterated Rating	Overweight	$11.00	Medium
9/8/2017	Oppenheimer	Lower Price Target	Outperform	$9.00 ➝ $6.00	Medium
8/10/2017	Rodman & Renshaw	Lower Price Target	Buy ➝ Buy	$18.00 ➝ $15.00	High
8/10/2017	HC Wainwright	Set Price Target	Buy	$15.00	High
8/10/2017	Oppenheimer	Set Price Target	Buy	$9.00	High
8/10/2017	Cantor Fitzgerald	Reiterated Rating	Buy	$11.00	High
7/31/2017	Canaccord Genuity	Set Price Target	Buy	$13.00	Low
7/18/2017	Oppenheimer	Reiterated Rating	Outperform	$9.00	Low
7/10/2017	Canaccord Genuity	Reiterated Rating	Buy	$13.00	Low
6/28/2017	Citigroup	Reiterated Rating	Sell	$3.70	Low
6/27/2017	BTIG Research	Reiterated Rating	Buy	$11.00	High
6/14/2017	Rodman & Renshaw	Reiterated Rating	Buy	$18.00	Medium
6/12/2017	HC Wainwright	Reiterated Rating	Buy	$18.00	Low
6/9/2017	Cantor Fitzgerald	Reiterated Rating	Overweight	$11.00	Low
6/1/2017	Cantor Fitzgerald	Initiated Coverage	Overweight	$11.00	High
5/31/2017	BTIG Research	Reiterated Rating	Buy	$11.00	Low
5/23/2017	Rodman & Renshaw	Reiterated Rating	Buy	$18.00	High
5/19/2017	HC Wainwright	Reiterated Rating	Buy	$18.00	Low
5/19/2017	Canaccord Genuity	Reiterated Rating	Buy	$13.00	Low
5/10/2017	Oppenheimer	Set Price Target	Buy	$10.00 ➝ $9.00	Medium
4/22/2017	BTIG Research	Reiterated Rating	Buy	$11.00	Low
4/11/2017	BTIG Research	Reiterated Rating	Buy	$11.00	Low
4/6/2017	Citigroup	Downgrade	Neutral ➝ Sell		High
3/29/2017	Rodman & Renshaw	Reiterated Rating	Buy	$18.00	Low
3/28/2017	HC Wainwright	Reiterated Rating	Buy	$18.00	Medium
3/21/2017	BTIG Research	Reiterated Rating	Buy	$11.00	Low
3/16/2017	HC Wainwright	Set Price Target	Buy	$18.00	High
3/3/2017	Rodman & Renshaw	Reiterated Rating	Buy	$18.00	N/A
3/2/2017	Oppenheimer	Set Price Target	Buy	$10.00	N/A
3/2/2017	Canaccord Genuity	Set Price Target	Buy	$13.00	N/A
3/2/2017	Guggenheim	Reiterated Rating	Outperform	$10.00	N/A
1/31/2017	Oppenheimer	Reiterated Rating	Outperform	$10.00	N/A
1/28/2017	Canaccord Genuity	Reiterated Rating	Buy	$13.00	N/A
1/27/2017	HC Wainwright	Set Price Target	Buy	$18.00	N/A
1/26/2017	BTIG Research	Reiterated Rating	Positive	$11.00	N/A
1/21/2017	Canaccord Genuity	Set Price Target	Buy	$13.00	N/A
1/21/2017	Oppenheimer	Set Price Target	Buy	$10.00	N/A
1/20/2017	BTIG Research	Reiterated Rating	Buy	$11.00	N/A
1/20/2017	Rodman & Renshaw	Boost Price Target	Buy	$17.00 ➝ $18.00	N/A
1/4/2017	Oppenheimer	Initiated Coverage	Outperform	$10.00	N/A
12/31/2016	Rodman & Renshaw	Boost Price Target	Buy	$16.00 ➝ $17.00	N/A
12/23/2016	Canaccord Genuity	Reiterated Rating	Buy	$13.00	N/A
12/23/2016	Rodman & Renshaw	Boost Price Target	Buy	$16.00 ➝ $17.00	N/A
12/23/2016	BTIG Research	Reiterated Rating	Buy	$11.00	N/A
12/15/2016	Roth Capital	Reiterated Rating	Buy	$6.50	N/A
12/13/2016	Rodman & Renshaw	Reiterated Rating	Buy	$15.00 ➝ $16.00	N/A
12/12/2016	HC Wainwright	Set Price Target	Buy	$16.00	N/A
12/9/2016	Canaccord Genuity	Set Price Target	Buy	$13.00	N/A
12/6/2016	BTIG Research	Reiterated Rating	Buy	$11.00	N/A
11/30/2016	Rodman & Renshaw	Reiterated Rating	Buy	$15.00	N/A
11/14/2016	Canaccord Genuity	Reiterated Rating	Buy	$13.00	N/A
11/11/2016	Rodman & Renshaw	Reiterated Rating	Buy	$15.00	N/A
10/24/2016	HC Wainwright	Set Price Target	Buy	$15.00	N/A
10/21/2016	Canaccord Genuity	Reiterated Rating	Buy	$13.00	N/A
10/17/2016	BTIG Research	Reiterated Rating	Positive	$11.00	N/A

(Data available from 9/19/2016 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

0 very positive mentions
0 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

2/21/2021

0 very positive mentions
0 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

3/23/2021

0 very positive mentions
0 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

4/22/2021

0 very positive mentions
0 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

5/22/2021

0 very positive mentions
0 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

6/21/2021

0 very positive mentions
0 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

7/21/2021

0 very positive mentions
0 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

8/20/2021

0 very positive mentions
0 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

9/19/2021

Current Sentiment

Recent Stories by Sentiment

Very Negative

No very negative mentions tracked during this time.

Negative

No negative mentions tracked during this time.

Positive

No positive mentions tracked during this time.

Very Positive

No very positive mentions tracked during this time.

Synergy Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies to treat gastrointestinal diseases and disorders. Its lead product is plecanatide, a novel uroguanylin based gastrointestinal platform that is traded under the TRULANCE name for the treatment of chronic idiopathic constipation and irritable bowel syndrome. The company also develops dolcanatide to treat mild-to-moderate ulcerative colitis. It has a licensing agreement with Cipher Pharmaceuticals Inc. to develop, market, distribute, and sell TRULANCE in Canada. Synergy Pharmaceuticals Inc. is headquartered in New York, New York. On December 12, 2018, Synergy Pharmaceuticals Inc. along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of New York.

Today's Range

Now: N/A

50 Day Range

MA: $0.02

$0.01

$0.03

52 Week Range

Now: N/A

Volume

N/A

Average Volume

6,081,307 shs

Market Capitalization

$7.44 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

4.94

Frequently Asked Questions

What sell-side analysts currently cover shares of Synergy Pharmaceuticals?

The following equities research analysts have issued research reports on Synergy Pharmaceuticals in the last twelve months:
View the latest analyst ratings for SGYP.

What is the current price target for Synergy Pharmaceuticals?

0 Wall Street analysts have set twelve-month price targets for Synergy Pharmaceuticals in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Synergy Pharmaceuticals in the next year.
View the latest price targets for SGYP.

What is the current consensus analyst rating for Synergy Pharmaceuticals?

Synergy Pharmaceuticals currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for SGYP.

What other companies compete with Synergy Pharmaceuticals?

Other companies that are similar to Synergy Pharmaceuticals include Amgen, Gilead Sciences, Regeneron Pharmaceuticals, Vertex Pharmaceuticals, Biogen, Seagen, Alnylam Pharmaceuticals, Exact Sciences, Novavax, Repligen, Incyte, BioMarin Pharmaceutical, Neurocrine Biosciences, United Therapeutics and Exelixis.

How do I contact Synergy Pharmaceuticals' investor relations team?

Synergy Pharmaceuticals' physical mailing address is 420 LEXINGTON AVENUE SUITE 2012, NEW YORK NY, 10170. The biopharmaceutical company's listed phone number is 212-297-0020 and its investor relations email address is [email protected] The official website for Synergy Pharmaceuticals is www.synergypharma.com.